Discharge Clinical Characteristics and 60-Day Readmission in Patients Hospitalized With Heart Failure.
CONCLUSION:: Hospitalizations for heart failure are markers of clinical instability. Future events after hospitalization are common in this patient population, and this study provides a novel understanding of clinical characteristics at the time of discharge that are associated with future outcomes, specifically 60-day heart failure readmissions. A consideration of these characteristics provides an additional perspective to guide clinical decision making and the evaluation of discharge readiness. PMID: 23612038 [PubMed - as supplied by publisher]
ConclusionsIn this high-risk low-income cohort, contributions of risk factors to HF varied, particularly by race. To reduce the population burden of HF, interventions tailored for specific race and sex groups may be warranted.Graphical abstract
Publication date: Available online 11 November 2019Source: Canadian Journal of CardiologyAuthor(s): Alexander C. Egbe, Keerthana Banala, Rahul Vojjini, Maria Najam, Fouad Khalil, Karim Osman, Mohamed Badawy, Jason H. Anderson, Nathaniel W. TaggartAbstractBackgroundElevated pulmonary artery wedge pressure (PAWP) is the hallmark of left heart failure, and is responsible for heart failure symptoms and mortality. Although, PAWP typically correlates with right atrial pressure (RAP), it is primarily dependent on left heart myocardial properties and volume status. Since right heart disease can occur in the absence of left heart d...
ConclusionsREDUCE LAP-HF II is designed to evaluate the clinical efficacy of the IASD device in patients with symptomatic HF with elevated LA pressure and LVEF≥40%.
Risk for subsequent cancer up with development of interim CV events, including heart failure, MI
Abstract Introduction: Metabolic syndrome (MetS) is defined as an association between diabetes, hypertension, obesity and dyslipidemia and an increased risk of cardiovascular disease. Mitral annular calcification (MAC) is associated with several cardiovascular disorders, including coronary artery disease, atrial fibrillation (AF), heart failure, ischemic stroke and increased mortality. The CHA2DS2-VASc score is used to estimate thromboembolic risk in AF. However, the association among MAC, MetS and thromboembolic risk is unknown and was evaluated in the current study. Methods: The study group consisted of 94 patients with ...
Abstract Atrial fibrillation is a common type of arrhythmia and is an important cause of stroke and heart failure. vitamin D is an emerging risk factor of AF, and is implicated in the pathophysiology of atrial fibrillation. It has been established that this vitamin is extensively involved in the regulation of both the renin angiotensin aldosterone system and the immune system. Epidemiological studies have not yet reached a consensus on the possible association between vitamin D deficiency and atrial fibrillation. Better research designs and methods can further clarify the relationship between the two.
We describe the case of a 64-year-old man who came to the emergency room due to acute heart failure and intermittent gastrointestinal bleeding. Treatment involves initial correction of anemia and heart failure followed by aortic valve replacement. The prosthesis used depends on the characteristics of each patient and valve replacement allows the resolution of bleeding in most cases. Gastrointestinal bleeding in patients with aortic stenosis is associated with severity of the valve obstruction. A mechanical prosthesis was used with no recurrent bleeding even with the need for lifelong anticoagulation therapy.
Authors: Attar A, Sayadi M Abstract INTRODUCTION: Currently, conflicting evidence exists among community-based studies as to whether Chronic kidney disease (CKD) is a Cardiovascular (CVD) risk equivalent. We aimed to evaluate the effect of CKD on CVD based on large trial results. METHODS: To perform a secondary analysis, we obtained the data of SPRINT trial from NHLBI Data Repository Center. 2646 subjects with baseline CKD and 6715 without CKD were enrolled. A composite of myocardial infarction, other acute coronary syndromes, stroke, heart failure, or death from cardiovascular causes was considered as primary ...
Commonly prescribed medications that exacerbate heart failure are often continued after — or even started during — HF hospitalization, new research suggests.Medscape Medical News
ConclusionsUbiquinol 400 mg/day for 3 months led to significant improvement in peripheral endothelial function in patients with HFrEF. Ubiquinol may be a therapeutic option for individuals with HFrEF. Large-scale randomized controlled trials of CoQ10 supplementation in patients with HFrEF are needed.Clinical Trial RegistrationJapanese University Hospital Medical Information Network (UMIN-ICDR). Clinical Trial identifier number UMIN000012604.